Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8QZNC)

Drug Name

PMID27998201-Compound-12 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Bone cancer	2B5Z	Patented	[1]
Cancer related pain	MG30	Patented	[1]

Cross-matching ID

TTD Drug ID: DM8QZNC

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cathepsin K (CTSK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Odanacatib	DM1EO3G	Osteoporosis	FB83.0	Phase 3	[2]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[3]
VEL-0230	DMDSC63	Rheumatoid arthritis	FA20	Phase 1	[4]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[1]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[1]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[5]
PMID27998201-Compound-15	DMOB8LU	Pain	MG30-MG3Z	Patented	[1]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1	DM1SH5R	Pain	MG30-MG3Z	Patented	[1]
PMID27998201-Compound-8	DMZK0SY	N. A.	N. A.	Patented	[1]
PMID27998201-Compound-10	DMVXTIL	Osteoporosis	FB83.0	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cathepsin L (CTSL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KGP94	DM2NZ6K	Coagulation defect	3B10.0	Clinical trial	[6]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[1]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[1]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[5]
PMID27998201-Compound-17	DMAZVHJ	Hair loss	ED70	Patented	[1]
Phenylalanine derivative 1	DMVYP8K	Glioma	2A00.0	Patented	[1]
PMID27998201-Compound-7	DMU4QYR	Abdominal aortic aneurysm	BD50.4	Patented	[1]
PMID27998201-Compound-6	DM0LGTY	N. A.	N. A.	Patented	[1]
PMID27998201-Compound-1	DM5QH4C	Coronavirus infection	1D92	Patented	[1]
PMID27998201-Compound-19	DM67RMX	Solid tumour/cancer	2A00-2F9Z	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cathepsin B (CTSB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[1]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[1]
PMID27998201-Compound-17	DMAZVHJ	Hair loss	ED70	Patented	[1]
PMID27998201-Compound-11	DMTV5NU	Metastatic cancer	2D50-2E2Z	Patented	[1]
PMID27998201-Compound-2	DMMAE3C	Alzheimer disease	8A20	Patented	[1]
PMID27998201-Compound-22	DMS9QA7	Alzheimer disease	8A20	Patented	[1]
PMID27998201-Compound-13	DMZHIM8	Hepatic fibrosis	DB93.0	Patented	[1]
Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	DMZ4B3W	Cerebral ischemia	8B11	Patented	[1]
PMID27998201-Compound-24	DM25BNZ	Glioma	2A00.0	Patented	[1]
L-006235-1	DMMEH12	Osteoarthritis	FA00-FA05	Preclinical	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cathepsin S (CTSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7625	DMDGPKS	Autoimmune disease	4A40-4A45	Phase 2	[8]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[3]
VBY- 891	DMTKPH4	Autoimmune diabetes	5A10	Phase 1	[9]
VBY- 036	DMULRYC	Neuropathic pain	8E43.0	Phase 1	[10]
VBY-129	DM4YIWK	Autoimmune diabetes	5A10	Phase 1	[11]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[1]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[1]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[5]
PMID27998201-Compound-17	DMAZVHJ	Hair loss	ED70	Patented	[1]
Phenylalanine derivative 1	DMVYP8K	Glioma	2A00.0	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cathepsin F (CTSF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[1]
PMID22686657C(R)-26	DM19D7G	Discovery agent	N.A.	Investigative	[12]
WRR-99	DM8ZA6K	Discovery agent	N.A.	Investigative	[13]
Benzoyl-Arginine-Alanine-Methyl Ketone	DMC7TNF	Discovery agent	N.A.	Investigative	[13]
WRR-112	DMP761U	Discovery agent	N.A.	Investigative	[13]
HOMOPHENYLALANINYLMETHANE	DMVBTHA	Discovery agent	N.A.	Investigative	[14]
BENZOYL-TYROSINE-ALANINE-METHYL KETONE	DMIRD8S	Discovery agent	N.A.	Investigative	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Drug(s) Targeting Cathepsin V (CTSV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID21277783C7	DMYBV8Q	Discovery agent	N.A.	Investigative	[15]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cathepsin B (CTSB)	TTF2LRI	CATB_HUMAN	Inhibitor	[1]
Cathepsin F (CTSF)	TTJOKD1	CATF_HUMAN	Inhibitor	[1]
Cathepsin K (CTSK)	TTDZN01	CATK_HUMAN	Inhibitor	[1]
Cathepsin L (CTSL)	TT36ETB	CATL1_HUMAN	Inhibitor	[1]
Cathepsin S (CTSS)	TTUMQVO	CATS_HUMAN	Inhibitor	[1]
Cathepsin V (CTSV)	TTSD9T1	CATL2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
2	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
3	From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
4	Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
5	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
6	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
7	Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
10	Clinical pipeline report, company report or official report of ViroBay.
11	Clinical pipeline report, company report or official report of ViroBay.
12	Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F. J Med Chem. 2012 Jun 28;55(12):5982-6.
13	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
14	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
15	Acridone alkaloids as potent inhibitors of cathepsin V. Bioorg Med Chem. 2011 Feb 15;19(4):1477-81.